TechsoMed
Tel Aviv, Israel· Est.
AI‑powered software that makes minimally invasive tumor ablation precise, reproducible, and curative.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10M
AI Company Overview
AI‑powered software that makes minimally invasive tumor ablation precise, reproducible, and curative.
Oncology
Technology Platform
AI‑driven image‑guided therapy software that fuses multimodal imaging into a real‑time 3‑D risk‑aware model with tissue‑response prediction.
Opportunities
Expansion of the BioTraceIO platform to additional organ systems and modalities, and licensing agreements with major device manufacturers.
Risk Factors
Regulatory hurdles for new indications, integration challenges with diverse hardware, and competition from larger imaging OEMs developing AI‑enabled solutions.
Competitive Landscape
Competes with imaging OEMs (Philips, Siemens, Canon) and AI startups; differentiation lies in FDA‑cleared tissue‑response prediction and vendor‑agnostic, end‑to‑end workflow.